Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Pembrolizumab in Solid tumor: NCT06894771 Clinical Landscape Report 2026
15 October 2026
NCT06894771 clinical landscape for Solid tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Vusolimogene oderparepvec-wtpg in Hemangiosarcoma: NCT06898970 Clinical Landscape Report 2026
15 October 2026
NCT06898970 clinical landscape for Hemangiosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dostarlimab-gxly in Mismatch repair-deficient Endometrial Carcinoma: NCT06897527 Clinical Landscape Report 2026
15 October 2026
NCT06897527 clinical landscape for Mismatch repair-deficient Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develop…
9 min read
RS-001(Ruishun Biotech) in High grade B-cell lymphoma: NCT06894693 Clinical Landscape Report 2026
15 October 2026
NCT06894693 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Avelumab in Advanced Urothelial Carcinoma: NCT06892860 Clinical Landscape Report 2026
15 October 2026
NCT06892860 clinical landscape for Advanced Urothelial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Lupus Nephritis: NCT06897930 Clinical Landscape Report 2026
15 October 2026
NCT06897930 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Equecabtagene Autoleucel in Lupus Nephritis: NCT06902844 Clinical Landscape Report 2026
15 October 2026
NCT06902844 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Chimeric Antigen Receptors T Cells(Guangzhou Women & Childrens Medical Center) in Lupus Nephritis: NCT06904729 Clinical Landscape Report 2026
15 October 2026
NCT06904729 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Axicabtagene Ciloleucel in Diffuse large B-cell lymphoma recurrent: NCT06902012 Clinical Landscape Report 2026
15 October 2026
NCT06902012 clinical landscape for Diffuse large B-cell lymphoma recurrent: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Afatinib Dimaleate in Lung Cancer: NCT06897735 Clinical Landscape Report 2026
15 October 2026
NCT06897735 clinical landscape for Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Enfortumab Vedotin-ejfv in Melanoma: NCT06906822 Clinical Landscape Report 2026
15 October 2026
NCT06906822 clinical landscape for Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Albumin-Bound Paclitaxel in Ovarian Cancer: NCT06906341 Clinical Landscape Report 2026
15 October 2026
NCT06906341 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.